OLE Study to Evaluate Safety / Efficacy of ZD4522

The purpose of this study is to assess the long term safety of Crestor.

Completed

Looking for future studies?

Key information

Conditions

Hypercholesterolaemia Dyslipidemias Hypercholesterolemia Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Completion of previous Crestor study as listed in the protocol.

Exclusion criteria

Pregnant or breast feeding women, or not using appropriate contraception.
Abnormal lab values as listed in the protocol.

Treatment and study plan

Rosuvastatin

Drug

Other names: Crestor

Primary outcomes

Safety, as determined by adverse events, laboratory data, physical examination and ECG.

Time frame: 12 weekly

Secondary outcomes

Success in achieving goals for Cholesterol levels

Time frame: 12 weekly

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

ZD4522 Long Term Extension Trial

Important dates

Study start: 1999
Study completion: 2005
First posted: Apr 7, 2008
Registry last updated: Mar 16, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed